Cefepime/Enmetazobactam-Reference-Cited by-同舟云学术

Cefepime/Enmetazobactam

Published:2024-08-12 Issue: Volume: Page:
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Staten Andrew R.¹,Baker Danial E.²^ORCID

Affiliation:

1. College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA

2. Drug Information Center, and Regents Professor in Pharmacy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/00185787241269112

Reference8 articles.

1. Exblifep (cefepime/enmetazobactam) [prescribing information]. Allecra Therapeutics SAS; February 2024.

2. National Institutes of Health. Cefepime enmetazobactam. ClinicalTrials.gov. Accessed March 22, 2024. https://www.clinicaltrials.gov/search?term=cefepime%20enmetazobactam.

3. Avycaz (ceftazidime/avibactam) [prescribing information]. AbbVie Inc; January 2024.

4. Zerbaxa (ceftolozane/tazobactam) [prescribing information]. Merck Sharp & Dohme Corp; April 2022.

5. Food and Drug Administration. Center for drug evaluation and research. Integrated review: Application number 216165Orig1s000 (cefepime and enmetazobactam injection). Published February 2024. Accessed March 22, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/216165Orig1s000IntegratedR.pdf